

Wraser Pharmaceuticals
100ct. Trezix Capsules
(840-10)

Booklet

3 9375"
4 0000"
3 9375"
3 9375"
4 0000"
4 1875"

2 1250"
2 1250"
2 1250"
2 1250"
2 1250"
2 1250"

4 1875"
4 0000"
3 9375"
3 9375"
4 0000"
3 9375"

(b) (4)
(b) (4)

TREZIX® Capsules
100ct. Trezix Capsules
250 mg (50 mg/100 mg)

Wraser Pharmaceuticals
 100ct. Trezix Capsules
 (840-10)

INDICATIONS AND USAGE

Trezix capsules are indicated for the treatment of patients with metastatic colorectal cancer who have received prior systemic therapy for metastatic disease.

CONTRAINDICATIONS

Trezix capsules are contraindicated in patients with a known hypersensitivity to any of the components of the formulation.

WARNINGS AND PRECAUTIONS

Diarrhea

Diarrhea is a common adverse effect of Trezix capsules. Patients should be advised to report any diarrhea to their healthcare provider. Patients should be advised to take appropriate measures to prevent dehydration and to report any signs of severe dehydration to their healthcare provider.

ADVERSE REACTIONS

The most common adverse reactions in patients receiving Trezix capsules are diarrhea, nausea, and vomiting.

DRUG INTERACTIONS

Trezix capsules may interact with other drugs, including but not limited to, anti-coagulants, anti-platelet agents, and anti-cancer drugs.

USE IN SPECIFIC POPULATIONS

Pregnancy, Fertility, and Birth Control

Trezix capsules are pregnancy category X. Patients should be advised to avoid pregnancy during treatment with Trezix capsules and for a period of time after the last dose.

ADJUNCT THERAPIES

Trezix capsules are used in combination with other anti-cancer drugs, including but not limited to, fluoropyrimidines, oxaliplatin, and irinotecan.

HOW SUPPLIED

Trezix capsules are supplied in 100-unit bottles.

STORAGE AND HANDLING

Trezix capsules should be stored at controlled room temperature (20° to 25°C).

DESCRIPTION

Trezix capsules are white, oval-shaped capsules with the Wraser Pharmaceuticals logo and the name "Trezix" embossed on one side.